Company Name Change

• Suven Pharmaceuticals Limited is now Cohance Lifesciences Limited.
• The name change reflects the company's evolution into a technology-driven global CDMO platform.

Key Highlights

• The name change has been approved by the Ministry of Corporate Affairs.
• The company will update the BSE and NSE with the new name.

What This Means for You

• The name change may not affect the company's operations or financials, but could be a strategic move for future growth.
• Monitor the company's performance and updates to make informed investment decisions.

Suven Pharmaceuticals Limited, a leading contract development and manufacturing organization (CDMO), has received final approval from the Department of Pharmaceuticals for foreign investment. This marks the final regulatory clearance required to implement the Scheme of Amalgamation between Cohance Lifesciences Limited and Suven Pharmaceuticals Limited. The merger will take effect from May 1, 2025, following the satisfaction of all prescribed conditions. The merged company will operate under the name Cohance Lifesciences Limited, subject to applicable regulatory approvals.